Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated renal cell carcinoma (RCC). Based on these results, we analyzed the outcome of bevacizumab plus erlotinib in Korean patients with HLRCC-associated RCC. Materials and Methods We retrospectively reviewed the efficacy and safety of bevacizumab plus erlotinib in patients with HLRCC-associated RCC who were confirmed to have germline mutations in fumarate hydratase. The primary endpoint was the objective response rate (ORR), while the secondary endpoints were progression-free survival (PFS) and overall survival (OS). Results We identified 10 patients with advanced HLRCC-associated RCC who received bevacizumab plus erlotinib. Median age at diagnosis was 41 years, and five of the patients had received the combination as first- or second-line treatments. The ORR was 50% and the median PFS and OS were 13.3 and 14.1 months, respectively. Most adverse events were predictable and manageable by conventional measures, except for one instance where a patient died of gastrointestinal bleeding. Conclusion This is the first real-world outcome of the treatment of advanced HLRCC-associated RCC. Bevacizumab plus erlotinib therapy showed promising activity with moderate toxicity. We should be increasingly aware of HLRCC-associated RCC and bevacizumab plus erlotinib should be a first-line treatment for this condition, unless other promising data are published.
Abstract
Purpose Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated renal cell carcinoma (RCC). Based on these results, we analyzed the outcome of bevacizumab plus erlotinib in Korean patients with HLRCC-associated RCC. Materials and Methods We retrospectively reviewed the efficacy and safety of bevacizumab plus erlotinib in patients with HLRCC-associated RCC who were confirmed to have germline mutations in fumarate hydratase. The primary endpoint was the objective response rate (ORR), while the secondary endpoints were progression-free survival (PFS) and overall survival (OS). Results We identified 10 patients with advanced HLRCC-associated RCC who received bevacizumab plus erlotinib. Median age at diagnosis was 41 years, and five of the patients had received the combination as first- or second-line treatments. The ORR was 50% and the median PFS and OS were 13.3 and 14.1 months, respectively. Most adverse events were predictable and manageable by conventional measures, except for one instance where a patient died of gastrointestinal bleeding. Conclusion This is the first real-world outcome of the treatment of advanced HLRCC-associated RCC. Bevacizumab plus erlotinib therapy showed promising activity with moderate toxicity. We should be increasingly aware of HLRCC-associated RCC and bevacizumab plus erlotinib should be a first-line treatment for this condition, unless other promising data are published.
참고문헌 (16)
- Tomlinson IP, "Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer", Nat Genet, 30, pp.406~410 (2002)
- Linehan WM, "Molecular pathways : Fumarate hydratase-deficient kidney cancer : targeting the Warburg effect in cancer", Clin Cancer Res, 19, pp.3345~3352 (2013)
- Lehtonen HJ, "Hereditary leiomyomatosis and renal cell cancer : update on clinical and molecular characteristics", Fam Cancer, 10, pp.397~411 (2011)
- Moch H, "The 2016 WHO classification of tumours of the urinary system and male genital organs-part A : renal, penile, and testicular tumours", Eur Urol, 70, pp.93~105 (2016)
- Srinivasan R, "New strategies in renal cell carcinoma : targeting the genetic and metabolic basis of disease", Clin Cancer Res, 21, pp.10~17 (2015)
- Yang L, "PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis", Nat Commun, 5, pp.4436~ (2014)
- De Rosa V, "Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer", Clin Cancer Res, 21, pp.5110~5120 (2015)
- Srinivasan R, "5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib", Eur J Cancer, 50(Suppl 6), pp.8~ (2014)
- "NCCN clinical practice guidelines in oncology. Kidney cancer (ver 2. 2019)" (2019)[URL]
- Grubb RL 3rd, "Hereditary leiomyomatosis and renal cell cancer : a syndrome associated with an aggressive form of inherited renal cancer", J Urol, 177, pp.2074~2079 (2007)
- Alrashdi I, "Hereditary leiomyomatosis and renal cell carcinoma : very early diagnosis of renal cancer in a paediatric patient", Fam Cancer, 9, pp.239~243 (2010)
- Merino MJ, "The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma(HLRCC)syndrome", Am J Surg Pathol, 31, pp.1578~1585 (2007)
- Menko FH, "Hereditary leiomyomatosis and renal cell cancer(HLRCC) : renal cancer risk, surveillance and treatment", Fam Cancer, 13, pp.637~644 (2014)
- Dienstmann R, "Toxicity as a biomarker of efficacy of molecular targeted therapies : focus on EGFR and VEGF inhibiting anticancer drugs", Oncologist, 16, pp.1729~1740 (2011)
- Sorich MJ, "Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors : a secondary analysis of pooled clinical trial data", Br J Cancer, 114, pp.1313~1317 (2016)
- Lattouf JB, "Structured assessment and followup for patients with hereditary kidney tumour syndromes", Can Urol Assoc J, 10, pp.E214~E222 (2016)